Artur Plawgo
Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart and elebsiran, a combination therapy developed for chronic Hepatitis B in partnership with Xencor (XNCR) and Alnylam Pharma (ALNY).
The ongoing MARCH trial is designed
